News Releases

Below are the latest News Releases for Clearmind Medicine Inc.

28

November

Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program
Read More
27

November

Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
Read More
21

November

Clearmind Medicine Announces 1-for-30 Reverse Share Split
Read More
17

November

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
Read More
15

November

Clearmind Medicine Announces Shareholders Meeting Results
Read More
5

October

Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
Read More
28

September

Clearmind Medicine to Present at the LD Micro Main Event XVI Investor Conference on October 4th
Read More
18

September

Clearmind Medicine Closes US$2.25 Million Public Offering
Read More
6

September

Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 for AUD
Read More
14

August

Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Read More
1

August

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP
Read More
11

July

Dr. Fatima Cody Stanford Joins Clearmind Medicine's Scientific Advisory Board
Read More
16

June

Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
Read More
22

May

Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Dis
Read More
17

May

Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Read More